Immunome Research
Open Access

Monoclonal Antibodies: Precision Tools in Modern Medicine

Jiang Shen^{* *}Correspondence: Jiang Shen, Department of Medicine, Fudan University, Shanghai, China, Email:

Author info »

Description

Monoclonal Antibodies (mAbs) are laboratory-produced molecules engineered to serve as substitutes for naturally occurring antibodies. They are designed to bind to specific antigens found on the surface of cells, making them valuable tools in both therapeutic and diagnostic applications. The development of mAbs has revolutionized the fields of immunology, oncology, and infectious disease treatment, leading to significant advancements in personalized medicine.

Discovery and development

The concept of mAbs was first introduced in 1975 by Georges Köhler and César Milstein, who developed a technique to produce a single type of antibody in large quantities. This amazing work allowed for the creation of hybridoma cells, which are formed by fusing an antibody-producing B cell with a myeloma (cancer) cell. The resulting hybrid cells can produce large amounts of a specific antibody, known as a monoclonal antibody.

The production process involves immunizing a mouse with a particular antigen, isolating the B cells that produce antibodies against that antigen, and fusing them with myeloma cells. The hybridoma cells are then screened to identify those that produce the desired antibody. Once selected, these cells can be cultured indefinitely, providing a continuous supply of the monoclonal antibody.

Mechanisms of action

mAbs can function through various mechanisms, depending on their design and intended use.

Neutralization: Many therapeutic mAbs work by binding to pathogens (such as viruses or bacteria) and neutralizing their ability to infect cells. For example, some mAbs can bind to the spike protein of the SARS-CoV-2 virus, preventing it from entering human cells and causing infection.

Antibody-Dependent Cell-mediated Cytotoxicity (ADCC): Certain mAbs can recruit immune cells to target and destroy cells that express specific antigens. This mechanism is especially useful in treating cancers, where mAbs can help the immune system recognize and eliminate malignant cells.

Complement activation: Some mAbs can activate the complement system, a part of the immune response that enhances the ability to clear pathogens and damaged cells. This activation leads to the lysis of target cells and promotes inflammation.

Blocking receptor-ligand interactions: mAbs can inhibit the interactions between receptors and their ligands, blocking signaling pathways that contribute to disease progression. This is particularly relevant in the treatment of cancers and autoimmune diseases.

Applications in medicine

mAbs have found applications across various medical fields:

Oncology: mabs have become a foundation in cancer treatment, providing targeted therapies for various cancers such as breast cancer, lymphoma, and leukemia. Drugs like trastuzumab (Herceptin) and rituximab (Rituxan) exemplify how mAbs can target specific tumor markers, leading to improved patient outcomes.

Autoimmune diseases: mAbs are used to treat autoimmune diseases by targeting specific immune pathways. For instance, adalimumab (Humira) is a mAb that inhibits Tumor Necrosis Factor-Alpha (TNF-á), a cytokine involved in inflammation, effectively reducing symptoms in conditions like rheumatoid arthritis and inflammatory bowel disease.

Infectious diseases: In addition to their role in treating cancers and autoimmune diseases, mAbs are being investigated and used for various infectious diseases. Recent developments include mAbs targeting viral infections, such as the use of palivizumab for Respiratory Syncytial Virus (RSV) and several mAbs for COVID-19.

Diagnostics: mAbs are also widely employed in diagnostic tests, including Enzyme-linked Immunosorbent Assay (ELISA), Western blotting, and immunohistochemistry. They can detect specific antigens in biological samples, aiding in disease diagnosis and monitoring.

Challenges and future directions

Despite their success, the development and use of mAbs face several challenges. Production can be complex and costly, and there may be issues with immunogenicity, where the patient’s immune system recognizes the mAb as foreign and mounts a response against it. Additionally, the development of resistance in target cells can diminish the effectiveness of these therapies over time.

Future research is focused on enhancing the efficacy and safety of mAbs, including the engineering of bispecific antibodies that can target multiple antigens simultaneously. Moreover, advancements in antibody technology, such as the development of Antibody-Drug Conjugates (ADCs) and nano bodies, are the way for novel therapeutic strategies.

Conclusion

mAbs represent a significant achievement in the field of biotechnology and medicine. Their ability to specifically target and bind to antigens makes them invaluable in treating a wide range of diseases, from cancer to infectious diseases. mAbs have shown promise in improving patient outcomes and advancing personalised medicine, making them a key component of current therapeutic approaches.